Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1). However, activation of t...
| Publicado en: | Current Oncology Vol. 29; no. 4; pp. 2871 - 2887 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156533384&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156533384 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Apr2022 vid: 29 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 156533384 10.3390/curroncol29040234 156533384 ppf: 2871 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. aug: au: Chen, Chieh-Hsun Yu, Hsin-Su Yu, Sebastian affil: Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan sug: ab: Immune checkpoint inhibitors (ICIs) have emerged as novel options that are effective in treating various cancers. They are monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death-ligand 1 (PD-L1). However, activation of the immune systems through ICIs may concomitantly trigger a constellation of immunologic symptoms and signs, termed immune-related adverse events (irAEs), with the skin being the most commonly involved organ. The dermatologic toxicities are observed in nearly half of the patients treated with ICIs, mainly in the form of maculopapular rash and pruritus. In the majority of cases, these cutaneous irAEs are self-limiting and manageable, and continuation of the ICIs is possible. This review provides an overview of variable ICI-mediated dermatologic reactions and describes the clinical and histopathologic presentation. Early and accurate diagnosis, recognition of severe toxicities, and appropriate management are key goals to achieve the most favorable outcomes and quality of life in cancer patients. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|